Want to see COGT full AI Analyst Report?
Top Page
Cogent Biosciences
(NASDAQ:COGT)
Select Model
Select Model
Rating:43Neutral
Price Target:
$30.00
▼(-18.48% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by weak financial performance (no revenue, expanding losses, and accelerating cash burn alongside higher debt) and bearish technical conditions (below key moving averages with negative MACD and sub-50 RSI). Corporate events provide a modest offset by improving operational preparedness and governance stability, but they are not large enough to outweigh the financial and trend headwinds.
Positive Factors
Manufacturing Readiness
The long-term supply agreement improves manufacturing preparedness for bezuclastinib and supports more reliable operational planning. Secured capacity and rolling forecasts can reduce execution uncertainty as the lead candidate advances, while declining minimum purchase obligations preserve flexibility over its lifecycle.
Negative Factors
Pre-Revenue Loss Profile
The absence of revenue leaves Cogent dependent on financing and future clinical or commercial success to fund operations. Expanding losses and negative gross profit indicate that current activities are not yet generating commercial scale, creating a persistent earnings and execution burden.
Read all positive and negative factors
Positive Factors
Negative Factors
Manufacturing Readiness
The long-term supply agreement improves manufacturing preparedness for bezuclastinib and supports more reliable operational planning. Secured capacity and rolling forecasts can reduce execution uncertainty as the lead candidate advances, while declining minimum purchase obligations preserve flexibility over its lifecycle.
Read all positive factors
Cogent Biosciences (COGT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.42B
Dividend YieldN/A
Average Volume (3M)2.25M
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue GrowthN/A
EPS Growth4.92%
CountryUS
Employees258
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.31
Shares Outstanding173,524,980
10 Day Avg. Volume2,362,216
30 Day Avg. Volume2,246,228
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)8.99
Price to Sales (P/S)0.00
P/FCF Ratio-21.50
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.63K
Enterprise Value/Ebitda-16.48
Forecast
1Y Price Target
$56.29Price Target Upside52.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.22
Revenue Forecast (FY)$5.98M
Cogent Biosciences Business Overview & Revenue Model
Company Description
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered...
Cogent Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.33M | -4.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -372.36M | -321.29M | -251.51M | -188.82M | -130.37M | -72.13M |
| Net Income | -377.18M | -328.94M | -255.86M | -192.41M | -140.24M | -72.27M |
Balance Sheet | ||||||
| Total Assets | 834.55M | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M |
| Cash, Cash Equivalents and Short-Term Investments | 792.30M | 900.76M | 287.08M | 265.71M | 259.28M | 219.68M |
| Total Debt | 244.26M | 253.15M | 17.47M | 18.85M | 19.65M | 3.15M |
| Total Liabilities | 302.16M | 301.24M | 71.61M | 55.63M | 45.08M | 17.91M |
| Stockholders Equity | 532.39M | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M |
Cash Flow | ||||||
| Free Cash Flow | -309.24M | -266.00M | -208.36M | -156.42M | -125.50M | -60.48M |
| Operating Cash Flow | -307.55M | -264.44M | -207.79M | -153.62M | -118.64M | -58.76M |
| Investing Cash Flow | -499.99M | -399.53M | 38.28M | -97.82M | -124.72M | -1.72M |
| Financing Cash Flow | 861.53M | 878.23M | 214.45M | 163.54M | 163.56M | 37.98M |
Cogent Biosciences Technical Analysis
Neutral
36.80
Price Trends
32.97
Negative
35.34
Negative
35.81
Negative
Market Momentum
-0.62
Negative
49.39
Neutral
85.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COGT, the sentiment is Neutral. The current price of 36.8 is above the 20-day moving average (MA) of 30.54, above the 50-day MA of 32.97, and above the 200-day MA of 35.81, indicating a neutral trend. The MACD of -0.62 indicates Negative momentum. The RSI at 49.39 is Neutral, neither overbought nor oversold. The STOCH value of 85.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COGT.
Cogent Biosciences Risk Analysis
Cogent Biosciences disclosed 61 risk factors in its most recent earnings report. Cogent Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cogent Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $8.96B | 113.64 | 12.03% | ― | 34.81% | 44.59% | |
62 Neutral | $5.93B | -53.38 | -15.65% | ― | ― | -76.46% | |
56 Neutral | $6.15B | -28.70 | -80.48% | ― | 53.51% | -3.31% | |
54 Neutral | $5.06B | -123.65 | 21.72% | ― | -42.84% | -106.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $5.22B | -5.52 | -410.20% | ― | 44.02% | -1101.02% | |
43 Neutral | $5.42B | -13.51 | -72.57% | ― | ― | 4.92% |
* Healthcare Sector Average
COGT
Cogent Biosciences
31.21
15.01
92.65%
PTCT
PTC Therapeutics
60.59
-6.49
-9.68%
PTGX
Protagonist Therapeutics
138.43
63.18
83.96%
RYTM
Rhythm Pharmaceuticals
89.27
-22.28
-19.97%
MIRM
Mirum Pharmaceuticals
80.39
8.81
12.31%
BLTE
Belite Bio, Inc. ADR
147.33
53.51
57.03%
Cogent Biosciences Corporate Events
Business Operations and Strategy
Cogent Biosciences Secures Long-Term Bezuclastinib Supply Deal
Positive
Sep 2, 2026
On September 1, 2026, Cogent Biosciences entered into a Commercial Supply Agreement with Hovione FarmaCiencia to manufacture bezuclastinib spray-dried dispersion and tablets, committing to purchase minimum percentages of its product requirements u...
Private Placements and FinancingRegulatory Filings and Compliance
Cogent Biosciences Announces $400 Million ATM Offering
Neutral
Aug 10, 2026
On August 10, 2026, Cogent Biosciences filed a prospectus supplement with the U.S. Securities and Exchange Commission to enable the sale of up to $400 million in common stock under an existing at-the-market Sales Agreement with Guggenheim Securiti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.